Frankfurt Awards €10.9 Million Electrical Installation Contract for U5 Extension
10 Aug 2026
Stadtbahn Entwicklung und Verkehrsinfrastrukturprojekte Frankfurt GmbH (SBEV) has awarded a €10.9 million contract to R+S solutions GmbH for the electrical installation of the underground section of the U5 tram line extension in Frankfurt am Main. The project covers the complete electrical installation for a new underground station, emergency exit, and tunnel route from Frankfurt Central Station to the ramp structure. Introduction Frankfurt am Main is expanding its public transport infrastructure with the extension of the U5 tram line through the Europaviertel district. This major infrastructure project, known as Stadtbahnstrecke B, Teilabschnitt 3, will improve connectivity and support the city's growing population. As part of this development, SBEV has awarded a €10.9 million contract for the electrical installation of the underground section. The contract, won by R+S solutions GmbH, covers the complete electrical installation for an underground station, emergency exit, and the entire underground route from Frankfurt Central Station to the ramp structure. The project involves extensive electrical works including transformers, switchgear, emergency power systems, UPS, lighting, safety lighting, and over 200 km of cables and wiring. Why This Contract Matters Reliable electrical infrastructure is essential for the safe and efficient operation of urban tram systems. This contract ensures that the U5 extension will have the electrical systems needed for safe passenger transport. This contract matters because it: Supports transport expansion: Enables the extension of the U5 tram line through Frankfurt's Europaviertel Major infrastructure project: Part of a significant urban transport development Comprehensive scope: Complete electrical installation for underground station and tunnel route Significant value: €10.9 million contract Quality focus: Evaluation combines Price (70%) and Quality (30%) Competitive process: Two bids received Contract Timeline Contract award notice published: 10 August 2026 (OJ S 152/2026) Winner chosen: 3 July 2026 Contract concluded: 20 July 2026 Coverage start date: Not specified Coverage end date: 39 months from start Contract Overview SBEV conducted an open procedure under the German Sector Regulations (SektVO) for this procurement. The contract covers the complete electrical installation for the underground section of the U5 tram extension. Key features include: Single lot: Complete electrical installation Duration: 39 months Value: €10,936,254.08 Evaluation: Price (70%) and Quality (30%) Project location: Frankfurt am Main, from Hauptbahnhof to the ramp structure Project type: Underground tram line extension (U5, Teilabschnitt 3 - Europaviertel) Key Contract Details Detail Information Contracting authority Stadtbahn Entwicklung und Verkehrsinfrastrukturprojekte Frankfurt GmbH (SBEV) Winning bidder R+S solutions GmbH Contract subject Electrical installation works (CPV 45311000) Procedure type Open procedure (SektVO) Legal basis EU Directive 2014/25/EU (Sector Directive) Awarded value (ex-VAT) €10,936,254.08 Contract duration 39 Months Bids received 2 EU funding None Covered by GPA Yes Evaluation criteria Price (70%), Quality (30%) Lowest admissible tender €10,936,254.08 Highest admissible tender €14,938,920.74 Project Scope The contract covers the complete electrical installation for the underground section of the U5 tram extension, including: Project Location Line: U5 tram line extension (Stadtbahnstrecke B, Teilabschnitt 3 - Europaviertel) Section: Underground section from Hauptbahnhof Frankfurt to the ramp structure Includes: One underground station (GP), emergency exit, and entire underground route City: Frankfurt am Main Electrical Installation Scope Transformers: Approx. 2 x dry-type transformers 800kVA / 10kV Emergency power: Approx. 1 x emergency generator 410kVA UPS system: Approx. 1 x UPS 200kW for 5 minutes Distribution boards: Approx. 2 x main low-voltage distribution boards, approx. 33 x sub-distribution boards/metering systems Control systems: Smart metering technology, KNX/DALI/CAN-Bus/Siemens S7 Safety lighting: Battery-operated emergency lighting systems Installation components: Approx. 1,440 units (switches, sockets, junction boxes, media ducts, etc.) Tunnel sockets: Approx. 57 tunnel socket combinations Lighting fixtures: Approx. 1,250 general and safety lighting fixtures, approx. 790 m of cove and linear luminaires Emergency signage: Approx. 150 escape route pictograms Cables and wiring: Approx. 206,600 m of cables and wires, approx. 700 m medium-voltage cables Cable routes: Approx. 10,000 m of cable trays, pipes, and ducts Fire protection: Approx. 150 m of fire protection ducts, approx. 12 m² of fire protection panels Earthing: Approx. 60 potential equalisation bars, approx. 4,300 m of copper earthing cable, approx. 260 copper cable earthing connectors Equipment: Use of aerial work platforms About the Contracting Authority Stadtbahn Entwicklung und Verkehrsinfrastrukturprojekte Frankfurt GmbH (SBEV) is a project company responsible for the development of tram and transport infrastructure projects in Frankfurt am Main. SBEV plans and implements major public transport infrastructure projects, including tram line extensions, station upgrades, and associated works. The company is a key player in Frankfurt's urban transport development. About the Winning Company R+S solutions GmbH is a large German electrical engineering company based in Fulda, Hesse. The company specialises in electrical installation, infrastructure projects, and complex electrical systems. R+S solutions has extensive experience in major infrastructure projects, including transport and public sector works. The company's winning bid of €10,936,254 was significantly below the highest tender of €14,938,920.74, demonstrating strong value for money. Procurement Analysis Procedure: An open procedure under the German Sector Regulations (SektVO) was used, which applies to procurement in the water, energy, transport, and postal services sectors. Competition: Two bids were received, representing limited but sufficient competition for a specialist electrical infrastructure project. Evaluation criteria: Price (70%) and Quality (30%). The quality criteria are evaluated according to a criteria catalogue (Leistungsbewertung gemäß Kriterienkatalog). Value for money: The winning bid (€10.94 million) was significantly below the highest bid (€14.94 million), a difference of approximately 27%. Duration: 39 months, reflecting the complexity and scale of the electrical installation works. No EU funding: The project is not financed with EU funds. Compliance: The procurement includes requirements for tariff compliance (Tariftreue) and minimum wage compliance (MiLoG). Additional Procurement Facts The contract is covered by the WTO's Government Procurement Agreement (GPA). No EU funds were used for this procurement. The procurement was not accelerated. No dynamic purchasing system was used. No framework agreement was used—this is a direct works contract. Two bids were received. The contract is subject to German sector regulations (SektVO). Disputes or review requests fall to the Vergabekammer des Landes Hessen beim Regierungspräsidium Darmstadt. The procurement includes requirements for tariff compliance and minimum wage compliance. Bieter are required to declare compliance with supply chain due diligence requirements. Market & Industry Perspective The German market for electrical infrastructure works in the transport sector is specialised, with a limited number of contractors capable of delivering complex underground electrical installations. This procurement attracted two bids, reflecting the specialist nature of the work. Key trends in this market include: Infrastructure investment: Significant public investment in urban transport infrastructure Specialist expertise: Electrical installation for underground transport infrastructure requires specialist skills Safety focus: High safety standards for electrical systems in public transport Compliance: Increasing regulatory requirements for tariff compliance and supply chain due diligence The significant price difference between the two bids (€10.94 million vs €14.94 million) suggests that R+S solutions had a competitive cost advantage or a more efficient approach to the project. Economic Significance At €10.9 million, this contract represents a significant investment in Frankfurt's public transport infrastructure. The project will: Improve public transport: Extend the U5 tram line to the Europaviertel district Support urban development: Enhance connectivity in a growing area of Frankfurt Create employment: Jobs for electrical engineers, technicians, and construction workers Generate tax revenue: The contract supports economic activity in the region Future Procurement Opportunities With the contract now awarded, future opportunities include: Other sections: Other sections of the U5 extension may be tendered separately Other infrastructure projects: SBEV may have other transport infrastructure projects Maintenance contracts: Future maintenance of the electrical systems Other cities: Similar tram and light rail projects in other German cities Opportunities for Suppliers While this contract is awarded, future opportunities exist for electrical engineering companies: Other sections: Other sections of the U5 extension may be tendered Other infrastructure projects: SBEV may have other transport infrastructure projects Subcontracting: Suppliers may find subcontracting opportunities on this or similar projects Other cities: Similar tram and light rail projects in other German cities What Businesses Should Watch SBEV's procurement notices for other transport infrastructure projects Similar tram and light rail projects in other German cities Changes to German sector regulations (SektVO) EU funding programmes for urban transport infrastructure Trends in sustainable and electric transport infrastructure GermanyTender Procurement Intelligence This electrical installation contract is a significant infrastructure project for Frankfurt's public transport system. Several features stand out: Scale: Comprehensive electrical installation for an underground tram section with station Value: €10.9 million contract for specialist electrical works Competition: Two bids received, with the winning bid significantly lower than the second bid Quality focus: The 30% quality weighting ensures that technical expertise and methodology are valued Regulatory compliance: The procurement includes tariff compliance, minimum wage, and supply chain due diligence requirements The significant price difference between the two bids suggests that R+S solutions submitted a highly competitive offer. The 39-month duration reflects the complexity and scale of the electrical installation works for an underground tram section. For suppliers, this procurement highlights the importance of: Competitive pricing: Price accounts for 70% of evaluation Technical quality: Quality accounts for 30% of evaluation Specialist expertise: Demonstrating expertise in electrical installation for transport infrastructure Regulatory compliance: Ensuring compliance with tariff, minimum wage, and supply chain requirements Supplier Takeaways Offer competitive pricing—price accounts for 70% of evaluation Demonstrate technical quality—30% of evaluation is quality-based Show expertise in electrical installation for transport infrastructure Ensure compliance with tariff, minimum wage, and supply chain due diligence requirements Monitor SBEV for other transport infrastructure opportunities Build relationships with project companies in the transport sector Key Takeaways SBEV awarded a €10.9 million electrical installation contract to R+S solutions GmbH Project: U5 tram extension underground section from Hauptbahnhof to ramp structure Includes: 1 underground station, emergency exit, and 1.1km+ tunnel route Scope: Complete electrical installation including transformers, switchgear, UPS, lighting, and 206 km of cables Evaluation: Price (70%) and Quality (30%) 2 bids received; winning bid €10.94M vs €14.94M Contract duration: 39 months Procurement under German Sector Regulations (SektVO) Conclusion This electrical installation contract represents a significant step forward for Frankfurt's U5 tram extension project. The comprehensive scope of works—from transformers and emergency power systems to over 200 km of cables—will ensure that the new underground section is equipped with safe, reliable electrical infrastructure. R+S solutions GmbH's successful bid, which was significantly lower than the second offer, demonstrates strong value for money for the public purse. The 39-month project duration reflects the complexity of installing electrical systems in an underground transport environment. As Frankfurt continues to invest in its public transport infrastructure, further opportunities will arise for electrical engineering companies with the right expertise and capabilities. Frequently Asked Questions Q: What is SBEV? Ans: Stadtbahn Entwicklung und Verkehrsinfrastrukturprojekte Frankfurt GmbH, a project company responsible for tram and transport infrastructure development in Frankfurt am Main. Q: What is the value of the contract? Ans: €10,936,254.08 (excluding VAT). Q: Who won the contract? Ans: R+S solutions GmbH. Q: What does the contract cover? Ans: Complete electrical installation for the underground section of the U5 tram extension, including transformers, switchgear, emergency power, UPS, lighting, safety lighting, and over 206 km of cables. Q: Where is the project located? Ans: Frankfurt am Main, from Hauptbahnhof to the ramp structure. Q: How long is the contract? Ans: 39 months. Q: How many bids were received? Ans: Two bids were received. Q: What were the evaluation criteria? Ans: Price (70%) and Quality (30%). Q: Is this contract funded by the EU? Ans: No, the procurement is not financed with EU funds. Source: EU Official Journal, Contract Award Notice 553185-2026, OJ S 152/2026, published 10 August 2026. body { font-family: sans-serif; margin: 20px; } table { border-collapse: collapse; width: 100%; margin: 15px 0; } th, td { border: 1px solid #ddd; padding: 8px; text-align: left; vertical-align: top; } th { background-color: #f2f2f2; } ul { padding-left: 20px; } h2 { margin-top: 30px; } h3 { margin-top: 20px; }
View Details
€163,000 Hamburg sports hall wall tender cancelled after zero bids.
07 Aug 2026
SBH | Schulbau Hamburg has cancelled a tender for impact wall (Prallwand) installation at the Carl-Götze-Schule sports hall extension after receiving no bids. The estimated €163,000 contract was part of a larger €11.7 million project to build a two-court sports hall with a daycare centre. The procurement was cancelled due to a change in needs. Introduction As part of the expansion of the Carl-Götze-Schule in Hamburg, SBH | Schulbau Hamburg is constructing a two-court sports hall with an integrated daycare centre. The project, with a total estimated value of €11.7 million, includes a DIN-compliant, competition-ready sports hall with spectator facilities. One of the specialist work packages within this larger project was the installation of the impact wall (Prallwand)—a critical safety feature for sports halls that protects athletes and walls from high-impact ball games. The contract, valued at an estimated €163,000, covered 345 m² of plywood impact wall panels, acoustic perforation, doors, and associated fittings. However, the tender received zero bids and was cancelled due to a change in needs, leaving the project to seek alternative procurement routes for this specialist work package. Why This Contract Matters Sports hall impact walls are essential safety features that protect both athletes and the building structure. The installation of a Prallwand requires specialist expertise in sports facility construction. This contract matters because it: Supports school sports infrastructure: Part of a larger project to expand the Carl-Götze-Schule Ensures safety: Impact walls protect athletes from injury and walls from damage Specialist work: Requires expertise in sports facility construction and acoustic solutions Part of larger investment: The overall project is worth €11.7 million Demonstrates market challenges: Zero bids indicate limited supplier interest or capacity Contract Timeline Contract award notice published: 7 August 2026 (OJ S 151/2026) Planned execution period: November 2026 – January 2026 (approximately 3 months) Outcome: Cancelled - change in needs, zero bids received Contract Overview SBH | Schulbau Hamburg conducted an open procedure (VOB/A) for this procurement. The contract covers the installation of the impact wall (Prallwand) for the new sports hall at Carl-Götze-Schule. Key features included: Single lot: Impact wall installation Duration: Approximately 3 months (November 2026 – January 2026) Estimated value: €163,000 (part of €11.7 million total project) Evaluation: Price only (100%) Procedure: Open procedure under VOB/A (German Construction Contract Procedures) Bids received: 0 Key Contract Details Detail Information Contracting authority SBH | Schulbau Hamburg Contract subject Impact wall installation (Prallwand) – CPV 45432210 Procedure type Open procedure (VOB/A) Legal basis EU Directive 2014/24/EU Estimated value (ex-VAT) €163,000.00 Total project value €11,735,000.00 Contract duration 3 Months (November 2026 – January 2026) Bids received 0 EU funding Fully or partially financed with EU funds Covered by GPA Yes Outcome Cancelled - change in needs Evaluation criteria Price only (100%) Project Scope The contract covered the installation of the impact wall (Prallwand) for the new sports hall at Carl-Götze-Schule. The scope included: Impact Wall Elements 345 m² Plywood impact wall panels for sports use 240 m² Additional acoustic perforation (3 mm) 130 m Base/skirting boards (Sockelleiste) Doors and Fittings 1 x Sports hall equipment room door (approx. 2.30 x 2.50 m) 1 x Sports hall equipment room door (approx. 2.45 x 2.50 m) 5 x Sports hall internal doors, single-leaf (approx. 1.16 x 2.20 m) 1 x Sports hall external door, double-leaf (approx. 2.235 x 2.53 m) 1 x Sports hall external door, single-leaf (approx. 1.735 x 2.53 m) 1 x Sports hall external door 2 x Steel U-frames (885 x 2,135 m) 2 x HPL internal doors 1 x HPL T-30 internal door, single-leaf (approx. 1.14 x 2.26 m) Other Elements 1 x Control room window (1.16 x 1.135 m) 2 x Equipment hatches (approx. 500 x 2500 mm) About the Contracting Authority SBH | Schulbau Hamburg is a public enterprise (Landesbetrieb) of the Free and Hanseatic City of Hamburg. SBH is responsible for planning, constructing, maintaining, and managing school properties across Hamburg, taking into account educational needs and economic principles. The organisation manages more than 400 schools and leases them to the Authority for Schools and Vocational Education (BSB). About the Winning Company No contract was awarded. The tender received zero bids and was cancelled due to a change in needs. No winning company exists for this procurement. Procurement Analysis Procedure: An open procedure under VOB/A (German Construction Contract Procedures) was used. Competition: Zero bids were received, indicating a complete lack of market interest. Evaluation criteria: Price only (100%). However, this criterion could not be applied as no bids were submitted. Cancellation reason: The procurement was cancelled due to a change in needs (Änderung des Bedarfs). EU funding: The project is fully or partially financed with EU funds. Project context: The contract was part of a larger €11.7 million project for a new sports hall and daycare centre. Reasons for Zero Bids Several factors may have contributed to the lack of bids: Specialist nature: Impact wall installation requires specialist expertise in sports facility construction and acoustic solutions Limited supplier pool: Only a small number of companies have the required expertise and certifications Small contract value: At €163,000, the contract may have been too small to attract larger contractors Timing: The planned execution period (November 2026 – January 2026) may have conflicted with other commitments Price-only evaluation: Suppliers may have been unwilling to compete solely on price for a specialist installation EU sanctions: The procurement included sanctions-related exclusion criteria (Russia sanctions), which may have limited the pool of eligible bidders Additional Procurement Facts The contract is covered by the WTO's Government Procurement Agreement (GPA). The project is fully or partially financed with EU funds. The procurement was not accelerated. No dynamic purchasing system was used. No framework agreement was used. The tender was cancelled due to a change in needs (Änderung des Bedarfs). Zero bids were received. The procurement included Russia sanctions-related exclusion criteria (5th EU sanctions package, April 2022). Disputes or review requests fall to the Vergabekammer bei der Behörde für Stadtentwicklung und Wohnen in Hamburg. The contract would have been subject to the Hamburg Transparency Act (HmbTG). Market & Industry Perspective The German construction market for specialist sports facility work is characterised by a limited number of specialised contractors. Impact wall installation requires expertise in sports hall construction, acoustic solutions, and compliance with DIN standards for sports facilities. Key trends in this market include: Specialist expertise: Limited pool of contractors with sports facility construction expertise Project bundling: Specialist work packages are often bundled with larger projects to attract bidders Capacity constraints: The construction sector is facing capacity constraints Price pressure: Price-only evaluation may discourage specialist contractors The cancellation of this tender highlights the challenges of procuring specialist construction work packages separately from larger projects. SBH may need to consider alternative procurement approaches for the impact wall installation, such as bundling it with other work packages or using a negotiated procedure. Economic Significance At €163,000, this contract represents a relatively small but important component of the larger €11.7 million sports hall project. The cancellation may delay the overall project timeline, as the impact wall installation is a critical safety feature that must be completed before the sports hall can be used. For specialist contractors, the cancellation represents a missed opportunity, though the small contract value may have limited its attractiveness. The broader €11.7 million project will still go ahead, and the impact wall work will need to be procured through alternative means. Future Procurement Opportunities With the procurement now cancelled, future opportunities include: Re-tender: The contract is likely to be re-tendered with possible adjustments Bundling: The work may be bundled with other specialist packages to attract bidders Negotiated procedure: SBH may use a negotiated procedure to engage directly with specialist contractors Main contractor: The work may be awarded to the main contractor for the sports hall project Opportunities for Suppliers While this procurement is cancelled, future opportunities exist for specialist construction companies: Re-tender: The contract is likely to be re-tendered—prepare for a second round Bundling: Be prepared to bid for larger bundled packages that include impact wall installation Engage early: Engage with SBH to understand their requirements and potential procurement changes Specialist certifications: Ensure certifications for sports facility construction are up to date Other schools: SBH manages over 400 schools—similar opportunities may arise What Businesses Should Watch Re-tendering of this contract or similar work packages from SBH SBH's procurement notices for other school construction projects Changes to procurement approach (e.g., bundling, negotiated procedures) EU funding programmes for school infrastructure Updates to DIN standards for sports facilities GermanyTender Procurement Intelligence This cancelled tender highlights several important lessons: Specialist market: Specialist construction work requires tailored procurement approaches Bundling matters: Small specialist work packages may not attract bidders; bundling with larger packages can improve participation Price-only evaluation: Price-only evaluation may not be suitable for specialist work where quality and expertise are critical Market engagement: Engaging with the market before procurement can help identify potential issues The zero-bid outcome is a clear signal to SBH that the procurement approach needs to be revised. For suppliers, the cancellation presents an opportunity to engage with SBH and influence the re-tender design. Supplier Takeaways Monitor for re-tendering of this contract—it is likely to return in a revised form Consider bidding for bundled packages that include impact wall installation Engage with SBH to understand their needs and procurement plans Maintain specialist certifications for sports facility construction Be prepared for price-competitive tenders, but also highlight quality and expertise Monitor SBH's procurement portal for future opportunities Key Takeaways SBH | Schulbau Hamburg cancelled a €163,000 impact wall tender after receiving zero bids Part of a larger €11.7 million sports hall project at Carl-Götze-Schule Scope: 345 m² plywood impact wall, 240 m² acoustic perforation, doors, and fittings Price-only evaluation (100%) Zero bids received Cancellation reason: change in needs Project fully or partially EU-funded Procurement included Russia sanctions exclusion criteria Likely to be re-tendered with possible procurement adjustments Conclusion The cancellation of this impact wall tender represents a setback for the Carl-Götze-Schule sports hall project in Hamburg. The zero-bid outcome highlights the challenges of procuring specialist construction work packages separately from larger projects, particularly when the contract value is relatively small and the supplier pool is limited. SBH | Schulbau Hamburg will need to revise its procurement approach to secure a contractor for this essential safety installation. Bundling the work with other packages, using a negotiated procedure, or adjusting the evaluation criteria may improve the chances of attracting bids. For specialist construction companies, the cancellation presents an opportunity to engage with SBH and influence the design of a re-tender, ensuring that the procurement is more attractive and accessible to qualified suppliers. Frequently Asked Questions Q: What is SBH | Schulbau Hamburg? Ans: A public enterprise (Landesbetrieb) of the Free and Hanseatic City of Hamburg responsible for planning, constructing, and managing school properties. Q: What was the value of the contract? Ans: €163,000 (estimated, excluding VAT). Q: What is the total project value? Ans: €11,735,000 for the larger sports hall and daycare centre project. Q: What does the contract cover? Ans: Impact wall (Prallwand) installation, including 345 m² of plywood panels, acoustic perforation, doors, and fittings. Q: How many bids were received? Ans: Zero. Q: Why was the procurement cancelled? Ans: Due to a change in needs (Änderung des Bedarfs). Q: What was the evaluation criterion? Ans: Price only (100%). Q: Is this contract funded by the EU? Ans: Yes, the project is fully or partially financed with EU funds. Q: What were the planned execution dates? Ans: November 2026 – January 2026 (approximately 3 months). Source: EU Official Journal, Contract Award Notice 549107-2026, OJ S 151/2026, published 7 August 2026. body { font-family: sans-serif; margin: 20px; } table { border-collapse: collapse; width: 100%; margin: 15px 0; } th, td { border: 1px solid #ddd; padding: 8px; text-align: left; vertical-align: top; } th { background-color: #f2f2f2; } ul { padding-left: 20px; } h2 { margin-top: 30px; } h3 { margin-top: 20px; }
View Details
DAK-Gesundheit awards €218 million generic pharmaceutical framework deal
06 Aug 2026
DAK-Gesundheit, on behalf of six German statutory health insurance funds (Ersatzkassen), has awarded a multi-lot framework agreement for generic pharmaceutical products worth up to €218 million over two years. The framework, divided into 168 lots covering various active substances, has been awarded to numerous pharmaceutical companies including PUREN Pharma, Viatris, Glenmark, and many others. Introduction Germany's statutory health insurance system relies on competitive procurement to manage pharmaceutical costs. Under § 130a Abs. 8 SGB V, health insurance funds are required to conclude discount agreements with pharmaceutical companies for generic medicines. The "Generika-Ersatzkassen 29" framework represents one of the largest such procurements in Germany. Coordinated by DAK-Gesundheit on behalf of six Ersatzkassen (replacement funds)—DAK-Gesundheit, TK, KKH, HEK, hkk, and BARMER—the framework covers 168 lots of active substances, running from January 2027 to December 2028, with a total estimated value of €218 million. This procurement ensures that millions of insured patients across Germany have access to cost-effective generic medicines through the statutory health insurance system. Why This Contract Matters Generic medicines account for a significant portion of pharmaceutical spending in Germany. By concluding discount agreements with pharmaceutical companies, health insurance funds secure rebates on the cost of medicines dispensed to their insured members. This framework matters because it: Covers essential medicines: 168 lots across a wide range of therapeutic areas Delivers cost savings: Discount agreements reduce pharmaceutical expenditure for health insurance funds Ensures supply security: Framework agreements guarantee availability of key medicines for insured patients Coordinates multiple funds: Six Ersatzkassen participate, leveraging collective buying power Involves extensive competition: Multiple pharmaceutical companies compete for individual lots Contract Timeline Contract award notice published: 6 August 2026 (OJ S 150/2026) Previous notice referenced: 148015-2026 Winner chosen: 6 July 2026 Contract concluded: 6 July 2026 Coverage start date: 1 January 2027 Coverage end date: 31 December 2028 (with optional extensions) Contract Overview The contract is a framework agreement for active substance-related discount agreements pursuant to § 130a Abs. 8 SGB V. The framework covers 168 lots, each representing a specific active substance (or group of substances) with specific pharmaceutical forms. Key features include: 168 lots: Individual lots for specific active substances and pharmaceutical forms Duration: 24 months (1 January 2027 – 31 December 2028) Optional extensions: Up to two six-month extensions (max 36 months) Evaluation: Price only (100% weighting) Total estimated value: €218,240,376.72 (excluding VAT) Framework type: Without reopening of competition Participants: 6 statutory health insurance funds (Ersatzkassen) Key Contract Details Detail Information Coordinating buyer DAK-Gesundheit Participating buyers DAK-Gesundheit, TK, KKH, HEK, hkk, BARMER Contract subject Generic pharmaceutical products (CPV 33600000) Procedure type Open procedure Legal basis EU Directive 2014/24/EU Total estimated value (ex-VAT) €218,240,376.72 Number of lots 168 Contract duration 1 January 2027 – 31 December 2028 (up to 36 months with extensions) EU funding None Covered by GPA No Winner chosen 6 July 2026 Contract signed 6 July 2026 Evaluation criteria Price only (100%) Framework type Framework agreement without reopening of competition Project Scope The framework covers generic pharmaceutical products across 168 lots, divided into active substance groups. Each lot corresponds to a specific active substance with defined pharmaceutical forms (e.g., tablets, creams, solutions). The lots are structured according to therapeutic areas. Sample Lots (Selected from 168) Lot 101: Mebeverin - A03AA04 (FTA / UTA) Lot 102: Mebeverin - A03AA04 (REK) Lot 103: Carglumsäure - A16AA05 Lot 104: Acitretin - D05BB02 Lot 105: Mometason - D07AC13 (CRE) Lot 107: Mometason - D07AC13 (SAL) Lot 108: Fesoterodin - G04BD11 Lot 109: Prednisolon - H02AB06 Lot 110: Ibandronsäure - M05BA06 (FTA) Lot 111: Ibandronsäure - M05BA06 (IFK) Lot 112: Morphin - N02AA01 (Oral unretardiert) Lot 113: Fentanyl - N02AB03 (LUT) Lot 114: Fentanyl - N02AB03 (SUT) Lot 115: Fentanyl - N02AB03 (TAB) Lot 116: Codein und Paracetamol - N02AJ06 (HKP / TAB) Lot 117: Codein und Paracetamol - N02AJ06 (SUP) Lot 118: Carbamazepin - N03AF01 Lot 119: Levetiracetam - N03AX14 (GRA) Lot 120: Entacapon - N04BX02 Lot 121: Diazepam - N05BA01 (TAB) Lot 122: Diazepam - N05BA01 (TEI) Lot 123: Acetylcystein - R05CB01 Lot 124: Ebastin - R06AX22 Lot 125: Lactulose - A06AD11 Lot 126: Glimepirid - A10BB12 Lot 127: Urapidil - C02CA06 Lot 128: Furosemid - C03CA01 Lot 129: Torasemid - C03CA04 Lot 130: Hydrochlorothiazid und Triamteren - C03EA21 Lot 131: Irbesartan und Hydrochlorothiazid - C09DA24 Lot 132: Ganirelix - H01CC01 Lot 133: Ibandronsäure - M05BA06 (IFE / ILO) Lot 134: Morphin - N02AA01 (ILO) Lot 135: Levetiracetam - N03AX14 (IFK) Lot 136: Zolpidem - N05CF02 Lot 137: Escitalopram - N06AB10 (TEI) Lot 138: Beclometason - R03BA01 Lot 139: Levocetirizin - R06AE09 Lot 140: Ursodeoxycholsäure - A05AA02 Lot 141: Acetylsalicylsäure - B01AC06 Lot 142: Carvedilol - C07AG02 Lot 143: Amlodipin - C08CA01 Lot 144: Telmisartan - C09CA07 Lot 145: Ezetimib - C10AX09 Lot 146: Tamsulosin - G04CA02 Lot 147: Valganciclovir - J05AB14 Lot 148: Letrozol - L02BG04 Lot 149: Apremilast - L04AA32 Lot 150: Fingolimod - L04AE01 Lot 151: Morphin - N02AA01 (Oral retardiert) Lot 152: Fentanyl - N02AB03 (PFT) Lot 153: Levetiracetam - N03AX14 (FTA) Lot 154: Escitalopram - N06AB10 (FTA / SMT) Lot 155: Bupropion - N06AX12 Lot 156: Mometason - R01AD09 Further Lots (DAK / KKH Group) Lot 201: Mebeverin - A03AA04 (FTA / UTA) [TK/hkk/HEK] Lot 202: Mebeverin - A03AA04 (REK) [TK/hkk/HEK] Lot 203: Carglumsäure - A16AA05 [TK/hkk/HEK] Lot 204: Acitretin - D05BB02 [TK/hkk/HEK] Lot 205: Mometason - D07AC13 (CRE) [TK/hkk/HEK] Lot 207: Mometason - D07AC13 (SAL) [TK/hkk/HEK] Lot 208: Fesoterodin - G04BD11 [TK/hkk/HEK] Lot 209: Prednisolon - H02AB06 [TK/hkk/HEK] Lot 210: Ibandronsäure - M05BA06 (FTA) [TK/hkk/HEK] Lot 211: Ibandronsäure - M05BA06 (IFK) [TK/hkk/HEK] Lot 212: Morphin - N02AA01 (Oral unretardiert) [TK/hkk/HEK] Lot 213: Fentanyl - N02AB03 (LUT) [TK/hkk/HEK] Lot 214: Fentanyl - N02AB03 (SUT) [TK/hkk/HEK] Lot 215: Fentanyl - N02AB03 (TAB) [TK/hkk/HEK] Lot 216: Codein und Paracetamol - N02AJ06 (HKP / TAB) [TK/hkk/HEK] Lot 217: Codein und Paracetamol - N02AJ06 (SUP) [TK/hkk/HEK] Lot 218: Carbamazepin - N03AF01 [TK/hkk/HEK] Lot 219: Levetiracetam - N03AX14 (GRA) [TK/hkk/HEK] Lot 220: Entacapon - N04BX02 [TK/hkk/HEK] Lot 221: Diazepam - N05BA01 (TAB) [TK/hkk/HEK] Lot 222: Diazepam - N05BA01 (TEI) [TK/hkk/HEK] Lot 223: Acetylcystein - R05CB01 [TK/hkk/HEK] Lot 224: Ebastin - R06AX22 [TK/hkk/HEK] Lot 225: Lactulose - A06AD11 [TK/hkk/HEK] Lot 226: Glimepirid - A10BB12 [TK/hkk/HEK] Lot 227: Urapidil - C02CA06 [TK/hkk/HEK] Lot 228: Furosemid - C03CA01 [TK/hkk/HEK] Lot 229: Torasemid - C03CA04 [TK/hkk/HEK] Lot 230: Hydrochlorothiazid und Triamteren - C03EA21 [TK/hkk/HEK] Lot 231: Irbesartan und Hydrochlorothiazid - C09DA24 [TK/hkk/HEK] Lot 232: Ganirelix - H01CC01 [TK/hkk/HEK] Lot 233: Ibandronsäure - M05BA06 (IFE / ILO) [TK/hkk/HEK] Lot 234: Morphin - N02AA01 (ILO) [TK/hkk/HEK] Lot 235: Levetiracetam - N03AX14 (IFK) [TK/hkk/HEK] Lot 236: Zolpidem - N05CF02 [TK/hkk/HEK] Lot 237: Escitalopram - N06AB10 (TEI) [TK/hkk/HEK] Lot 238: Beclometason - R03BA01 [TK/hkk/HEK] Lot 239: Levocetirizin - R06AE09 [TK/hkk/HEK] Lot 240: Ursodeoxycholsäure - A05AA02 [TK/hkk/HEK] Lot 241: Acetylsalicylsäure - B01AC06 [TK/hkk/HEK] Lot 242: Carvedilol - C07AG02 [TK/hkk/HEK] Lot 243: Amlodipin - C08CA01 [TK/hkk/HEK] Lot 244: Telmisartan - C09CA07 [TK/hkk/HEK] Lot 245: Ezetimib - C10AX09 [TK/hkk/HEK] Lot 246: Tamsulosin - G04CA02 [TK/hkk/HEK] Lot 247: Valganciclovir - J05AB14 [TK/hkk/HEK] Lot 248: Letrozol - L02BG04 [TK/hkk/HEK] Lot 249: Apremilast - L04AA32 [TK/hkk/HEK] Lot 250: Fingolimod - L04AE01 [TK/hkk/HEK] Lot 251: Morphin - N02AA01 (Oral retardiert) [TK/hkk/HEK] Lot 252: Fentanyl - N02AB03 (PFT) [TK/hkk/HEK] Lot 253: Levetiracetam - N03AX14 (FTA) [TK/hkk/HEK] Lot 254: Escitalopram - N06AB10 (FTA / SMT) [TK/hkk/HEK] Lot 255: Bupropion - N06AX12 [TK/hkk/HEK] Lot 256: Mometason - R01AD09 [TK/hkk/HEK] Further Lots (BARMER Group) Lot 301: Mebeverin - A03AA04 (FTA / UTA) [BARMER] Lot 302: Mebeverin - A03AA04 (REK) [BARMER] Lot 303: Carglumsäure - A16AA05 [BARMER] Lot 304: Acitretin - D05BB02 [BARMER] Lot 305: Mometason - D07AC13 (CRE) [BARMER] Lot 307: Mometason - D07AC13 (SAL) [BARMER] Lot 308: Fesoterodin - G04BD11 [BARMER] Lot 309: Prednisolon - H02AB06 [BARMER] Lot 310: Ibandronsäure - M05BA06 (FTA) [BARMER] Lot 311: Ibandronsäure - M05BA06 (IFK) [BARMER] Lot 312: Morphin - N02AA01 (Oral unretardiert) [BARMER] Lot 313: Fentanyl - N02AB03 (LUT) [BARMER] Lot 314: Fentanyl - N02AB03 (SUT) [BARMER] Lot 315: Fentanyl - N02AB03 (TAB) [BARMER] Lot 316: Codein und Paracetamol - N02AJ06 (HKP / TAB) [BARMER] Lot 317: Codein und Paracetamol - N02AJ06 (SUP) [BARMER] Lot 318: Carbamazepin - N03AF01 [BARMER] Lot 319: Levetiracetam - N03AX14 (GRA) [BARMER] Lot 320: Entacapon - N04BX02 [BARMER] Lot 321: Diazepam - N05BA01 (TAB) [BARMER] Lot 322: Diazepam - N05BA01 (TEI) [BARMER] Lot 323: Acetylcystein - R05CB01 [BARMER] Lot 324: Ebastin - R06AX22 [BARMER] Lot 325: Lactulose - A06AD11 [BARMER] Lot 326: Glimepirid - A10BB12 [BARMER] Lot 327: Urapidil - C02CA06 [BARMER] Lot 328: Furosemid - C03CA01 [BARMER] Lot 329: Torasemid - C03CA04 [BARMER] Lot 330: Hydrochlorothiazid und Triamteren - C03EA21 [BARMER] Lot 331: Irbesartan und Hydrochlorothiazid - C09DA24 [BARMER] Lot 332: Ganirelix - H01CC01 [BARMER] Lot 333: Ibandronsäure - M05BA06 (IFE / ILO) [BARMER] Lot 334: Morphin - N02AA01 (ILO) [BARMER] Lot 335: Levetiracetam - N03AX14 (IFK) [BARMER] Lot 336: Zolpidem - N05CF02 [BARMER] Lot 337: Escitalopram - N06AB10 (TEI) [BARMER] Lot 338: Beclometason - R03BA01 [BARMER] Lot 339: Levocetirizin - R06AE09 [BARMER] Lot 340: Ursodeoxycholsäure - A05AA02 [BARMER] Lot 341: Acetylsalicylsäure - B01AC06 [BARMER] Lot 342: Carvedilol - C07AG02 [BARMER] Lot 343: Amlodipin - C08CA01 [BARMER] Lot 344: Telmisartan - C09CA07 [BARMER] Lot 345: Ezetimib - C10AX09 [BARMER] Lot 346: Tamsulosin - G04CA02 [BARMER] Lot 347: Valganciclovir - J05AB14 [BARMER] Lot 348: Letrozol - L02BG04 [BARMER] Lot 349: Apremilast - L04AA32 [BARMER] Lot 350: Fingolimod - L04AE01 [BARMER] Lot 351: Morphin - N02AA01 (Oral retardiert) [BARMER] Lot 352: Fentanyl - N02AB03 (PFT) [BARMER] Lot 353: Levetiracetam - N03AX14 (FTA) [BARMER] Lot 354: Escitalopram - N06AB10 (FTA / SMT) [BARMER] Lot 355: Bupropion - N06AX12 [BARMER] Lot 356: Mometason - R01AD09 [BARMER] About the Contracting Authority DAK-Gesundheit is one of Germany's largest statutory health insurance funds (Gesetzliche Krankenkasse). In this procurement, DAK-Gesundheit acts as the coordinating buyer on behalf of six Ersatzkassen (replacement funds): DAK-Gesundheit – Germany's oldest health insurance fund TK-Techniker Krankenkasse – One of the largest health insurance funds in Germany KKH - Kaufmännische Krankenkasse – Commercial health insurance fund HEK - Hanseatische Krankenkasse – Hanseatic health insurance fund hkk - Handelskrankenkasse – Trade health insurance fund BARMER – One of Germany's largest health insurance funds The procurement is conducted under the legal framework of § 130a Abs. 8 SGB V, which mandates discount agreements for generic medicines. About the Winning Companies The framework has been awarded to numerous pharmaceutical companies, with multiple winners per lot. Key winners include: PUREN Pharma GmbH & Co. KG – Large German pharmaceutical company (Netherlands-owned) – Won 23 lots Viatris Healthcare GmbH – Large German pharmaceutical company (French/German-owned) – Won 3 lots Recordati Rare Diseases Germany GmbH – Large German pharmaceutical company – Won 3 lots Glenmark Arzneimittel GmbH – Large German pharmaceutical company – Won 14 lots BG ALIUD / STADAPHARM GbR – Large German pharmaceutical consortium – Won 30 lots BG Hexal 1A Pharma GbR – Large German pharmaceutical consortium – Won 32 lots Accord Healthcare GmbH – Large German pharmaceutical company (UK-owned) – Won 5 lots Phoenix Labs Unlimited Company – Large Irish pharmaceutical company – Won 4 lots Grünenthal GmbH – Large German pharmaceutical company – Won 3 lots HEC Pharm GmbH – Large German pharmaceutical company (Chinese-owned) – Won 3 lots Micro Labs GmbH – Large German pharmaceutical company (Indian-owned) – Won 10 lots BG Heumann / Heunet GbR – Large German pharmaceutical consortium – Won 15 lots Zentiva Pharma GmbH – Large German pharmaceutical company (Luxembourg-owned) – Won 14 lots BG TEVA ratiopharm GbR – Large German pharmaceutical consortium – Won 17 lots Betapharm Arzneimittel GmbH – Large German pharmaceutical company (Indian-owned) – Won 7 lots Medical Valley Invest AB – Large Swedish pharmaceutical company – Won 5 lots And many others Contract values are unpublished (justified as trade secrets). Procurement Analysis Procedure: An open procedure was used, allowing any interested economic operator to submit a tender. Competition: Competition varied by lot, with 0-13 bidders per lot. Some lots received no bids and were not awarded. Evaluation criteria: Price only (100% weighting). This is standard for discount agreements under German pharmaceutical procurement law. Framework structure: Framework agreements without reopening of competition. Foreign Subsidies Regulation (FSR): All awarded lots had notifications submitted with administrative closure of FSR preliminary review procedures. Lots not awarded: Several lots received no bids or were cancelled due to technical/procedural errors (see results below). Additional Procurement Facts The contract is not covered by the WTO Government Procurement Agreement (GPA). No EU funds were used for this procurement. The procurement was not accelerated. No dynamic purchasing system was used. Framework agreements without reopening of competition were used. Each lot was awarded separately to one or multiple suppliers (3-5 per lot typically). No subcontracting was declared by any winner. Disputes or review requests fall to the Vergabekammer des Bundes beim Bundeskartellamt. Contract values are not published (justified as trade secrets). Market & Industry Perspective The German generic pharmaceutical market is one of the largest in Europe, with significant public procurement through statutory health insurance funds. The Ersatzkassen framework is a key procurement mechanism, driving competition and cost savings in the pharmaceutical sector. Key trends in this market include: Price pressure: Price-only evaluation creates intense competition, driving down pharmaceutical costs for health insurance funds Consolidation: Bidding consortia (Bietergemeinschaften) are common, allowing smaller companies to compete for larger lots International ownership: Many winning companies have international parent companies (Netherlands, UK, India, China, Luxembourg, Ireland, Sweden) Foreign Subsidies Regulation (FSR): All awarded lots have undergone FSR review, reflecting the EU's focus on foreign subsidies in procurement Supply security: Framework agreements ensure stable supply of generic medicines to insured patients Economic Significance At an estimated value of €218 million over two years (with optional extensions), this framework represents a significant portion of pharmaceutical spending for the participating health insurance funds. The discount agreements secured through this procurement will reduce pharmaceutical expenditure, ultimately benefiting insured members through lower contributions. For the winning pharmaceutical companies, the framework provides stable, predictable revenue streams over the contract period. The multi-lot structure allows companies to bid for specific active substances where they have competitive advantages. Future Procurement Opportunities With the framework now in place through December 2028 (potentially extended to December 2029), future opportunities include: Contract extensions: Up to two six-month extensions (potentially through December 2029) Re-tender: The next Ersatzkassen generics framework (Generika-Ersatzkassen 30) will be tendered in 2028-2029 Other health insurance funds: Similar frameworks are conducted by other German health insurance funds Additional active substances: New active substances may be added to future frameworks Opportunities for Suppliers While this framework is now awarded, future opportunities exist for pharmaceutical companies: Bidding consortia: Forming consortia (Bietergemeinschaften) can enable smaller companies to compete for larger lots Competitive pricing: Price-only evaluation means competitive pricing is paramount International presence: Companies with international parent companies can leverage global supply chains for cost advantages FSR compliance: Ensuring compliance with the Foreign Subsidies Regulation is essential for participation What Businesses Should Watch Re-tendering of the Ersatzkassen generics framework (Generika-Ersatzkassen 30) Similar frameworks from other German health insurance funds (AOK, IKK, etc.) Changes to German pharmaceutical procurement law (SGB V, AMG) EU Foreign Subsidies Regulation (FSR) developments New active substances and therapeutic areas GermanyTender Procurement Intelligence This framework is a textbook example of large-scale pharmaceutical procurement in Germany. Several features are notable: Scale: 168 lots with a total estimated value of €218 million Price-only evaluation: Standard for discount agreements, reflecting the statutory requirement to secure cost savings Multi-supplier model: Most lots have 3-5 winners, ensuring supply security and competition Consortia bidding: Many lots were won by consortia (Bietergemeinschaften), allowing smaller companies to compete effectively FSR compliance: All awarded lots have undergone FSR review, reflecting the EU's focus on foreign subsidies The participation of major international pharmaceutical companies (including companies owned in the Netherlands, UK, India, China, Luxembourg, Ireland, and Sweden) highlights the global nature of the generic pharmaceutical market. Supplier Takeaways Price is the sole evaluation criterion—competitive pricing is essential Forming consortia can enable smaller companies to compete for larger lots Ensure FSR compliance for participation in EU procurement Monitor re-tendering cycles (typically every 2-3 years) Build relationships with health insurance funds to understand their procurement strategies Consider international partnerships to leverage global supply chains Key Takeaways DAK-Gesundheit coordinated a €218 million generics framework on behalf of six Ersatzkassen 168 lots covering various active substances and pharmaceutical forms Price-only evaluation (100% weighting) Winners include 20+ pharmaceutical companies and consortia Contract duration: January 2027 – December 2028 (up to 36 months with extensions) FSR compliance required for all lots Some lots not awarded due to no bids or procedural errors Contract values not published (trade secrets) Conclusion This framework agreement represents a significant procurement in the German generic pharmaceutical market. By coordinating the purchasing power of six Ersatzkassen, DAK-Gesundheit has secured discount agreements across 168 lots, ensuring cost-effective access to generic medicines for millions of insured patients. The framework's structure—with multiple winners per lot, consortia bidding, and price-only evaluation—reflects the competitive nature of the German pharmaceutical market. The participation of both German and international companies highlights the global nature of the generic pharmaceutical supply chain. As the framework runs through 2028 (with potential extensions), the winning pharmaceutical companies will provide essential medicines to the German healthcare system, while health insurance funds benefit from cost savings that help manage pharmaceutical expenditure. Frequently Asked Questions Q: What is Generika-Ersatzkassen 29? Ans: A framework agreement for discount contracts on generic pharmaceutical products, coordinated by DAK-Gesundheit on behalf of six German statutory health insurance funds (Ersatzkassen). Q: How many lots are there? Ans: 168 lots, each covering a specific active substance with defined pharmaceutical forms. Q: Who are the participating health insurance funds? Ans: DAK-Gesundheit, TK-Techniker Krankenkasse, KKH, HEK, hkk, and BARMER. Q: What is the total value of the framework? Ans: €218,240,376.72 (excluding VAT), estimated. Q: What was the evaluation criterion? Ans: Price only (100% weighting). Q: How long is the framework? Ans: 24 months (1 January 2027 – 31 December 2028), with up to two six-month extensions (max 36 months). Q: Are contract values published? Ans: No, contract values are not published (justified as trade secrets). Q: What is the Foreign Subsidies Regulation (FSR)? Ans: An EU regulation that requires review of foreign subsidies that may distort competition in the internal market. Q: Which companies won? Ans: Over 20 pharmaceutical companies and consortia, including PUREN Pharma, Viatris, Glenmark, BG ALIUD/STADAPHARM, BG Hexal 1A Pharma, Accord Healthcare, Phoenix Labs, Grünenthal, HEC Pharm, Micro Labs, BG Heumann/Heunet, Zentiva, BG TEVA ratiopharm, and many others. Source: EU Official Journal, Contract Award Notice 544832-2026, OJ S 150/2026, published 6 August 2026. body { font-family: sans-serif; margin: 20px; } table { border-collapse: collapse; width: 100%; margin: 15px 0; } th, td { border: 1px solid #ddd; padding: 8px; text-align: left; vertical-align: top; } th { background-color: #f2f2f2; } ul { padding-left: 20px; } h2 { margin-top: 30px; } h3 { margin-top: 20px; }
View Details